Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 420-428 , November 2007

Cancer Imaging With Fluorine-18–Labeled Choline Derivatives

  • Sandi A. Kwee, MD

      Affiliations

    • University of Hawaii John A. Burns School of Medicine, Honolulu, HI.
    • Hamamatsu/Queen’s PET Imaging Center, The Queen’s Medical Center, Honolulu, HI.
    • Corresponding Author InformationAddress reprint requests to Sandi A. Kwee, MD, Assistant Professor, University of Hawaii John A. Burns School of Medicine, The Queen’s Medical Center–Nuclear Medicine Department, 1301 Punchbowl Street, Honolulu, HI 96813.
    • ,
  • Timothy R. DeGrado, PhD

      Affiliations

    • Department of Radiology, Indiana University School of Medicine, Indianapolis, IN.
    • ,
  • Jean Noel Talbot, MD

      Affiliations

    • Department of Nuclear Medicine, Hôpital Tenon, AP-HP, et Université Pierre et Marie Curie, Paris, France.
    • ,
  • Fabrice Gutman, MD

      Affiliations

    • Department of Nuclear Medicine, Hôpital Tenon, AP-HP, et Université Pierre et Marie Curie, Paris, France.
    • ,
  • Marc N. Coel, MD

      Affiliations

    • Hamamatsu/Queen’s PET Imaging Center, The Queen’s Medical Center, Honolulu, HI.

References 

  1. Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res. 1996;16:1375–1380
  2. Nakagami K, Uchida T, Ohwada S, et al. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res. 1999;90:419–424
  3. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002;296:580–583
  4. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–995
  5. Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med. 1997;38:842–847
  6. Yoshida S, Nakagomi K, Goto S, et al. C-choline positron emission tomography in bladder cancer: report of four cases. Int J Urol. 2006;13:829–831
  7. Picchio M, Treiber U, Beer AJ, et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: Correlation with histopathologic findings. J Nucl Med. 2006;47:938–944
  8. Gofrit ON, Mishani E, Orevi M, et al. Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol. 2006;176:940–944discussion 944.
  9. Farsad M, Schiavina R, Castellucci P, et al. Detection and localization of prostate cancer: Correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642–1649
  10. de Jong IJ, Pruim J, Elsinga PH, et al. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol. 2002;42:18–23
  11. de Jong IJ, Pruim J, Elsinga PH, et al. Visualisation of bladder cancer using (11)C-choline PET: First clinical experience. Eur J Nucl Med Mol Imaging. 2002;29:1283–1288
  12. Hara T, Kosaka N, Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43:187–199
  13. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res. 2001;61:110–117
  14. Bansal A, Wang S, Harris R, et al. Biodisposition and Metabolism of [18F]fluorocholine in cultured 9L glioma cells and subcutaneous 9L tumor model. [Abstract] Mol Imaging Biol. 2006;8:78
  15. Gilissen C, de Groot TJ, Bronfman F, et al. Evaluation of 18F-FA-4 and 11C-pipzA-4 as radioligands for the in vivo evaluation of the high-affinity choline uptake system. J Nucl Med. 2003;44:269–275
  16. Hara T, Bansal A, Degrado TR. Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging. 2006;5:498–509
  17. Spaeth N, Wyss MT, Weber B, et al. Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: Implications for separation of radiation necrosis from tumor recurrence. J Nucl Med. 2004;45:1931–1938
  18. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805–1814
  19. Iwata R, Pascali C, Bogni A, et al. [18F]fluoromethyl triflate, a novel and reactive [18F]fluoromethylating agent: Preparation and application to the on-column preparation of [18F]fluorocholine. Appl Radiat Isot. 2002;57:347–352
  20. Lim J, Dorman E, Cabral C. Automated production of[18F]FECh and [18F]FCH: Preparation and use of [18F]fluoroalkane sulfonates and fluoroalkylation agents. J. Label Compd Radiopharm. 2003;46:S403
  21. Hara T. 18F-fluorocholine: A new oncologic PET tracer. J Nucl Med. 2001;42:1815–1817
  22. Cuadrado A, Carnero A, Dolfi F, et al. Phosphorylcholine: A novel second messenger essential for mitogenic activity of growth factors. Oncogene. 1993;8:2959–2968
  23. Breeuwsma AJ, Pruim J, Jongen MM, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging. 2005;32:668–673
  24. Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: Implications for diagnosis and therapy. Expert Rev Mol Diagn. 2006;6:821–829
  25. Yamaguchi T, Lee J, Uemura H, et al. Prostate cancer: A comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32:742–748
  26. Kwee SA, Coel MN, Lim J, et al. Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation. J Neuroimaging. 2004;14:285–289
  27. Padma MV, Adineh M, Pugar K, et al. Functional imaging of a large demyelinating lesion. J Clin Neurosci. 2005;12:176–178
  28. Kohli V KS, Coel MN. Comparison between 2D and 3D Prostate PET Imaging. J Nucl Med 2006;46:370P.
  29. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274–292
  30. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996;199:751–756
  31. Price DT, Coleman RE, Liao RP, et al. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168:273–280
  32. Basillote JB, Armenakas NA, Hochberg DA, et al. Influence of prostate volume in the detection of prostate cancer. Urology. 2003;61:167–171
  33. Naughton CK, Miller DC, Mager DE, et al. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol. 2000;164:388–392
  34. Kwee SA, Coel MN, Lim J, et al. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2005;173:252–255
  35. Kwee SA, Wei H, Sesterhenn I, et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med. 2006;47:262–269
  36. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: Initial experience. Radiology. 2005;235:623–628
  37. Talbot JN, Gutman F, Fartoux L, et al. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: Preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006;33:1285–1289
  38. Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: Meaningful at PSA < 5 ng/ml?. Mol Imaging Biol. 2006;8:43–48
  39. Cimitan M, Bortolus R, Morassut S, et al. [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387–1398
  40. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med. 2006;36:73–92
  41. Martorana G, Schiavina R, Corti B, et al. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol. 2006;176:954–960discussion 960.
  42. Kwee SA, Ko JP, Jiang CS, et al. Solitary brain lesions enhancing at MR imaging: Evaluation with fluorine 18 fluorocholine PET. Radiology. 2007;244:557–565
  43. Ohtani T, Kurihara H, Ishiuchi S, et al. Brain tumour imaging with carbon-11 choline: Comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med. 2001;28:1664–1670
  44. Goebell E, Paustenbach S, Vaeterlein O, et al. Low-grade and anaplastic gliomas: Differences in architecture evaluated with diffusion-tensor MR imaging. Radiology. 2006;239:217–222
  45. Provenzale JM, McGraw P, Mhatre P, et al. Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology. 2004;232:451–460
  46. Burtscher IM, Skagerberg G, Geijer B, et al. Proton MR spectroscopy and preoperative diagnostic accuracy: An evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR Am J Neuroradiol. 2000;21:84–93
  47. Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: Normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics. 1998;18:805–823discussion 823-804.
  48. Wang T, Sun YE, Yao SL, et al. [Value of carbon-11 choline positron emission tomography in patients with pulmonary abnormalities]. Zhonghua Wai Ke Za Zhi. 2006;44:405–408
  49. Roivainen A, Parkkola R, Yli-Kerttula T, et al. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum. 2003;48:3077–3084
  50. Sasaki T. [11C]choline uptake in regenerating liver after partial hepatectomy or CCl4-administration. Nucl Med Biol. 2004;31:269–275
  51. Kubota K, Furumoto S, Iwata R, et al. Comparison of 18F-fluoromethylcholine and 2-deoxy-D-glucose in the distribution of tumor and inflammation. Ann Nucl Med. 2006;20:527–533
  52. Wyss MT, Weber B, Honer M, et al. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging. 2004;31:312–316

 Supported by U.S. Department of Defense Prostate Cancer Research Program Grant PC04130, and National Institutes of Health/ National Cancer Institute grant CA108620.

PII: S0001-2998(07)00086-4

doi: 10.1053/j.semnuclmed.2007.07.003

Seminars in Nuclear Medicine
Volume 37, Issue 6 , Pages 420-428 , November 2007

Article Tools

* Image Usage & Resolution